CA2223519A1 - Procedes d'evaluation de cibles antimicrobiennes - Google Patents

Procedes d'evaluation de cibles antimicrobiennes Download PDF

Info

Publication number
CA2223519A1
CA2223519A1 CA 2223519 CA2223519A CA2223519A1 CA 2223519 A1 CA2223519 A1 CA 2223519A1 CA 2223519 CA2223519 CA 2223519 CA 2223519 A CA2223519 A CA 2223519A CA 2223519 A1 CA2223519 A1 CA 2223519A1
Authority
CA
Canada
Prior art keywords
gene
microbe
activity
level
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2223519
Other languages
English (en)
Inventor
Bret Benton
Keith Bostian
Pamela Contag
Molly B. Schmid
Thomas R. Parr, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trine Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2223519A1 publication Critical patent/CA2223519A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Procédés d'évaluation de gènes microbiens en tant que cibles pour des composés qui inhibent la croissance d'un microbe ou modifient la pathogénèse d'un microbe, et d'évaluation de l'effet thérapeutique espéré de composés qui inhibent une réaction d'une cellule microbienne apparentée à l'expression d'un gène spécifique. Ces procédés mettent en application des microbes recombinés qui contiennent des produits de recombinaison ou des modifications d'ADN, de sorte que le niveau d'activité des produits de régions codantes associées à ces produits de recombinaison ou à ces modifications peut être commandé par mise en contact du microbe avec une petite molécule spécifique ou autre changement spécifique artificiel du milieu. Ces microbes recombinés peuvent être utilisés dans des modèles d'infection afin d'évaluer l'effet de la modification artificielle du niveau d'activité du produit d'un gène.
CA 2223519 1995-06-07 1996-05-28 Procedes d'evaluation de cibles antimicrobiennes Abandoned CA2223519A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48211895A 1995-06-07 1995-06-07
US08/482,118 1995-06-07

Publications (1)

Publication Number Publication Date
CA2223519A1 true CA2223519A1 (fr) 1996-12-19

Family

ID=23914751

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2223519 Abandoned CA2223519A1 (fr) 1995-06-07 1996-05-28 Procedes d'evaluation de cibles antimicrobiennes

Country Status (4)

Country Link
EP (1) EP0830457A1 (fr)
AU (1) AU5939996A (fr)
CA (1) CA2223519A1 (fr)
WO (1) WO1996040979A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649143B1 (en) 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US7255851B2 (en) 1994-07-01 2007-08-14 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US5962249A (en) * 1995-12-22 1999-10-05 Microcide Pharmaceuticals, Inc. Sized-based marker identification technology
US6846625B1 (en) * 1998-01-09 2005-01-25 Cubist Pharmaceuticals, Inc. Method for identifying validated target and assay combination for drug development
US6878516B1 (en) * 1998-01-16 2005-04-12 Pharmacia & Upjohn Company Autoregulatory system for validating microbial genes as possible antimicrobial targets using a tetracycline-controllable element
WO1999036554A1 (fr) * 1998-01-16 1999-07-22 Pharmacia & Upjohn Company Systeme autoregulateur de validation de genes microbiens en tant qu'eventuelles cibles antimicrobiennes utilisant un element regulable par la tetracycline
WO2000036106A2 (fr) 1998-12-17 2000-06-22 Xenogen Corporation Evaluation non-invasive d'une reponse physiologique chez un mammifere
US6720139B1 (en) 1999-01-27 2004-04-13 Elitra Pharmaceuticals, Inc. Genes identified as required for proliferation in Escherichia coli
US6610503B1 (en) 1999-03-17 2003-08-26 Xenogen Corporation Animal models for predicting sepsis mortality
DE60044514D1 (de) 1999-05-05 2010-07-15 Phylogica Ltd Isolierung von biologischen Modulatoren aus Bibliotheken mit biologisch vielvältigen Genfragmenten
GB9915399D0 (en) * 1999-07-02 1999-09-01 Zeneca Ltd Method
US6737245B1 (en) 1999-09-08 2004-05-18 Xenogen Corporation Luciferase expression cassettes and methods of use
WO2001034810A2 (fr) 1999-11-09 2001-05-17 Elitra Pharmaceuticals, Inc. Genes indispensables a une proliferation microbienne et antisens a cet egard
US6867348B1 (en) 1999-12-16 2005-03-15 Xenogen Corporation Methods and compositions for screening for angiogenesis modulating compounds
IT1311335B1 (it) 1999-12-21 2002-03-12 Otc Optical Technologies Ct S Procedimento e dispositivo per realizzare reticoli in fibra ottica.
US7056728B2 (en) 2000-07-06 2006-06-06 Xenogen Corporation Compositions and methods for use thereof in modifying the genomes of microorganisms
EP1373496A4 (fr) * 2001-02-22 2004-10-27 Praecis Pharm Inc Procedes d'identification de peptides modulant un processus biologique
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
AU2023215360A1 (en) * 2022-02-01 2024-09-12 Azitra Inc Expression of the human lekti gene from the chromosome of staphylococcus epidermidis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0303925B1 (fr) * 1987-08-17 1995-06-07 F. Hoffmann-La Roche Ag Séquence très répressible pour le contrôle de l'expression
FR2648149A1 (fr) * 1989-06-09 1990-12-14 Agronomique Inst Nat Rech Souches modifiees de bacteries phytophathogenes et leurs applications pour le criblage de molecules utilisables pour la protection des cultures
AU3825995A (en) * 1994-10-04 1996-04-26 New York University Blocking expression of virulence factors in s. aureus

Also Published As

Publication number Publication date
AU5939996A (en) 1996-12-30
EP0830457A1 (fr) 1998-03-25
WO1996040979A1 (fr) 1996-12-19

Similar Documents

Publication Publication Date Title
CA2223519A1 (fr) Procedes d'evaluation de cibles antimicrobiennes
Grohmann et al. Conjugative plasmid transfer in gram-positive bacteria
Zhang et al. Regulated gene expression in Staphylococcus aureus for identifying conditional lethal phenotypes and antibiotic mode of action
Wolz et al. Agr‐independent regulation of fibronectin‐binding protein (s) by the regulatory locus sar in Staphylococcus aureus
Thomas et al. Regulation of autolysis-dependent extracellular DNA release by Enterococcus faecalis extracellular proteases influences biofilm development
Fidopiastis et al. LitR, a new transcriptional activator in Vibrio fischeri, regulates luminescence and symbiotic light organ colonization
Vivas et al. Xenorhabdus nematophilus as a model for host-bacterium interactions: rpoS is necessary for mutualism with nematodes
Wulff‐Strobel et al. LcrQ and SycH function together at the Ysc type III secretion system in Yersinia pestis to impose a hierarchy of secretion
Schnorpfeil et al. Target evaluation of the non‐coding csRNAs reveals a link of the two‐component regulatory system CiaRH to competence control in S treptococcus pneumoniae R 6
Alexeyev et al. Membrane topology of the Rickettsia prowazekii ATP/ADP translocase revealed by novel dual pho-lac reporters
Page et al. Characterization of the interaction partners of secreted proteins and chaperones of Shigella flexneri
Molina et al. A two‐partner secretion system is involved in seed and root colonization and iron uptake by Pseudomonas putida KT2440
Abi Khattar et al. The dlt operon of Bacillus cereus is required for resistance to cationic antimicrobial peptides and for virulence in insects
Tang et al. Characterization of the BatI (Bacteroides aerotolerance) operon in Bacteroides fragilis: isolation of a B. fragilis mutant with reduced aerotolerance and impaired growth in in vivo model systems
Eberhart et al. Characterization of a novel microcin that kills enterohemorrhagic Escherichia coli O157: H7 and O26
Ben‐Yaakov et al. The regulatory network of Vibrio parahaemolyticus type VI secretion system 1
US20030054537A1 (en) Regulable gene expression in Gram-positive bacteria
Muniz et al. Erwinia carotovora Evf antagonizes the elimination of bacteria in the gut of Drosophila larvae
Zink et al. Importance of srtA and srtB for growth of Bacillus anthracis in macrophages
She et al. Negative interplay between biofilm formation and competence in the environmental strains of Bacillus subtilis
Turlan et al. SpxA1, a novel transcriptional regulator involved in X‐state (competence) development in Streptococcus pneumoniae
US5962249A (en) Sized-based marker identification technology
EP1034308A1 (fr) Procede mettant en oeuvre des sequences antisens d'expression pour produire des cellules mutantes exprimees de maniere conditionnelle
Das et al. Molecular characterization of Vibrio cholerae Δ relA Δ spoT double mutants
Marco et al. Conditional survival as a selection strategy to identify plant-inducible genes of Pseudomonas syringae

Legal Events

Date Code Title Description
FZDE Dead